Figure 3.
Effect of IFX on determination of ATI concentration. Aliquots of human serum from healthy volunteers were spiked with commercial ATI, to the final concentrations indicated, and with IFX (CT-P13, final concentration 8 μg/mL) or its vehicle. Serum aliquots were diluted 30-fold, subjected to acidic pretreatment, and injected over immobilised IFX and IgG (the latter for evaluation of non-specific binding). The points indicate the specific SPR signal due to the binding of flowing ATI to immobilised IFX.